Data Sheet 1_Pan-cancer analysis reveals TRA16 as a master regulator of human carcinogenesis.pdf by Yanyan Zhu (32035)

“…Importantly, patients with high TRA16 expression demonstrated elevated TMB and decreased stromal and immune features.</p>Discussion<p>These findings highlight TRA16 as a potential master regulator of oncogenic processes, contributing to tumor progression through coordinated regulation of cell cycle genes, intercellular signaling, and genomic instability. …”

Data that underlies this paper. by Henan Si (21512689)

“…<div><p>Background</p><p>Sporotrichosis is a subcutaneous mycosis caused by members of the genus <i>Sporothrix</i>, among which <i>Sporothrix globosa</i> (<i>S. globosa</i>) is the predominant etiological agent in Asia. …”

In-Hospital Mortality by Admission Day and Serum Sodium Category (Excluding Hypernatremia). by Rajkumar Rajendram (22505442)

Autophagy facilitates CTV infection in <i>Nicotiana benthamiana.</i> by Yongle Zhang (11355546)

Docetaxel and quercetin-loaded lipid nanocarrier optimized by quality by design for glioblastoma therapy: a ligand-conjugated and therapeutic repurposing approach by Zufika Qamar (22259678)

“…Compared to non-conjugated NLC and (DTX-QUR) suspension (SUS), Tf-(DTX-QUR) NLC showed 3.6- and 5.8-fold decrease in IC₅₀, respectively. Cellular uptake studies demonstrated significantly (<i>***p < 0.001</i>) high internalization of Tf-conjugated NLC to U87-MG cells. …”

Table 1_Interobserver variability in organ delineation on radiotherapy treatment planning for nasopharyngeal carcinoma: A dosimetric and prognostic analysis.docx by Meining Chen (18693919)

“…Compared to standard delineations, all four physicians showed decreased TCPs (average decrease in ΔTCP >1%) and a significant increase in NTCPs of OARs. …”

PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

PCAIs inhibit NCI-H23 cell line viability. by Matthew D. Gregory (19929096)

“…However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. …”

PCAIs disrupt actin filaments in NCI-H23 cells. by Matthew D. Gregory (19929096)

“…However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. …”

PCAIs suppress 3D NCI-H23 cell invasion. by Matthew D. Gregory (19929096)

“…However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. …”

PCAIs suppress NCI-H23 cancer cell migration. by Matthew D. Gregory (19929096)

“…However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. …”

PCAIs induce apoptosis in NCI-H23 cells. by Matthew D. Gregory (19929096)

“…However, CRAF/RAF1 phosphorylation decreased by 40%, suggesting significant changes in the KRAS/MAPK signaling patterns. …”

The effect of PCAIs on BRAF and RAF1 (CRAF) protein phosphorylation. by Matthew D. Gregory (19929096)

TRV-based silencing of <i>NbGAPCs</i> in <i>Nicotiana benthamiana</i> plants. by Yongle Zhang (11355546)

CTV p20 interacts with NbSGS3 and mediates autophagic degradation of NbSGS3. by Yongle Zhang (11355546)

Effects of activators and inhibitors on TcPiezo channels. by Guozhong Huang (673424)

“…Downregulation of <i>TcPiezo2</i> expression (+Tet) showed a significant decrease of lysosomal Ca²⁺ release as in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1013105#ppat.1013105.g004" target="_blank">Fig 4A</a>. …”

Diagnostic criteria for Alcoholic cardiomyopathy. by Fei Yan (128878)

“…</p><p><b>Conclusion:</b> In 2021, ACM remained a significant global health burden, particularly affecting middle-aged and elderly populations with distinct demographic disparities. …”

TRV-based silencing of <i>NbATG5</i> and <i>NbATG7</i> in <i>Nicotiana benthamiana</i> plants. by Yongle Zhang (11355546)

The effect of PCAIs on MAPK pathway protein phosphorylation. by Matthew D. Gregory (19929096)

Roxadustat has risks of reversible central hypothyroidism in patients undergoing hemodialysis: a single-center retrospective cohort study by Emiko Otsuka (7519313)

“…Here, we retrospectively analyzed thyroid-stimulating hormone (TSH), free thyroxine (FT4), and free triiodothyronine (FT3) levels in 51 patients (mean age: 72.3 ± 10.7 years; 58.8% male) undergoing hemodialysis before, during, and after halting roxadustat treatment. TSH levels were significantly decreased from a median of 2.46 (interquartile range:1.60–4.51) mU/L before roxadustat treatment to 1.36 (0.72–2.41) mU/L during treatment (<i>p</i> < 0.001), and improved to 2.56 (1.78–4.63) mU/L after halting roxadustat (<i>p</i> < 0.001). …”